GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION
    1.
    发明申请
    GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION 审中-公开
    有用于冠状动脉疾病和心肌梗塞风险评估的遗传变异

    公开(公告)号:US20100120045A1

    公开(公告)日:2010-05-13

    申请号:US12598180

    申请日:2008-04-30

    IPC分类号: C12Q1/68 C07H21/00

    摘要: The invention relates to methods of risk assessment and diagnosis of susceptibility to coronary artery disease and myocardial infarction, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with coronary artery disease and myocardial infarction. The invention also relates to methods for use of such polymorphic markers for predicting drug response to drugs for treating cardiovascular disease, or for monitoring the effectiveness of such drugs. The invention further relates to kits encompassing reagents for use in these methods.

    摘要翻译: 本发明涉及通过评估发现与冠状动脉疾病和心肌梗死相关的某些多态性标志物的等位基因的存在或不存在而对冠状动脉疾病和心肌梗死的易感性进行风险评估和诊断的方法。 本发明还涉及使用这种多态性标记物预测用于治疗心血管疾病的药物的药物应答或用于监测这些药物的有效性的方法。 本发明还涉及包含用于这些方法的试剂的试剂盒。

    GENETIC MARKERS FOR RISK MANAGEMENT OF CARDIAC ARRHYTHMIA
    2.
    发明申请
    GENETIC MARKERS FOR RISK MANAGEMENT OF CARDIAC ARRHYTHMIA 有权
    心脑血管病风险管理遗传标记

    公开(公告)号:US20090325163A1

    公开(公告)日:2009-12-31

    申请号:US12302463

    申请日:2007-12-05

    IPC分类号: C12Q1/68 G06F19/00

    摘要: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.

    摘要翻译: 本发明涉及通过评估发现与心房颤动,心房颤动和中风相关的多态性标记处的等位基因的存在或不存在来确定心律失常易感性的方法和方法,包括心房颤动,心房扑动和中风。 本发明还涉及包含用于评估这种标记的试剂的试剂盒,以及用于利用这种敏感性标记物的诊断方法,用途和程序。

    Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
    3.
    发明申请
    Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment 失效
    心肌梗塞,中风和PAOD的易感基因; 治疗方法

    公开(公告)号:US20070280917A1

    公开(公告)日:2007-12-06

    申请号:US11270804

    申请日:2005-11-09

    摘要: Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.

    摘要翻译: FLAP和LTA4H基因的多态性通过遗传关联分析显示为心肌梗死(MI)和ACS以及中风和PAOD的敏感性标志物。 描述了针对治疗和诊断应用的途径,用于鉴定那些处于发展中心,ACS,中风或PAOD风险的患者。 本发明还提供了通过向受试者施用包含治疗有效量的体内抑制白细胞三烯合成的MI治疗剂的组合物的组合,在具有包括黑非洲血统的种族的人类受试者中预防MI治疗的方法。 本发明还提供了包含白三烯合成抑制剂和他汀类的组合物以及使用这些组合物降低患有MI,ACS,中风和/或PAOD风险的人类受试者中的C-反应蛋白的方法。

    Susceptibility gene for myocardial infarction and stroke
    4.
    发明申请
    Susceptibility gene for myocardial infarction and stroke 失效
    心肌梗死和中风的易感基因

    公开(公告)号:US20050112611A1

    公开(公告)日:2005-05-26

    申请号:US10829674

    申请日:2004-04-22

    申请人: Anna Helgadottir

    发明人: Anna Helgadottir

    摘要: Linkage of Myocardial Infarction (MI) to a locus on chromosome 13q12-13 is disclosed. In particular, the FLAP gene within this locus is shown by association analysis to be a susceptibility gene for MI and stroke. Pathway targeting for drug delivery and diagnosis applications in identifying those at risk of developing MI or stroke, in particular are described.

    摘要翻译: 公开了心肌梗死(MI)与染色体13q12-13位点的连锁。 特别地,通过关联分析将该基因座内的FLAP基因显示为MI和中风的易感基因。 具体描述了用于药物递送和诊断应用的靶向用于鉴定发生MI或中风的风险的途径。

    GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE
    8.
    发明申请
    GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE 审中-公开
    与心脏病相关的遗传易感性变异

    公开(公告)号:US20120208709A1

    公开(公告)日:2012-08-16

    申请号:US13451210

    申请日:2012-04-19

    IPC分类号: C40B20/00 C12Q1/68

    摘要: The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease, MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers.

    摘要翻译: 本发明涉及通过评估发现与心血管疾病相关的某些多态性标记的等位基因的存在或不存在来诊断心血管疾病易感性的方法,包括冠状动脉疾病,MI,腹主动脉动脉瘤,颅内动脉瘤再狭窄和外周动脉疾病 。 本发明还涉及包含用于评估这种标记的试剂的试剂盒,以及评估对治疗剂的应答可能性的方法和使用这种标记物的方法。

    Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
    9.
    发明授权
    Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype 失效
    诊断心肌梗死易感性和筛选LTA4H单倍型的方法

    公开(公告)号:US08158362B2

    公开(公告)日:2012-04-17

    申请号:US11270804

    申请日:2005-11-09

    IPC分类号: C12Q1/68 C07H21/04

    摘要: Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.

    摘要翻译: FLAP和LTA4H基因的多态性通过遗传关联分析显示为心肌梗死(MI)和ACS以及中风和PAOD的敏感性标志物。 描述了针对治疗和诊断应用的途径,用于鉴定那些处于发展中心,ACS,中风或PAOD风险的患者。 本发明还提供了通过向受试者施用包含治疗有效量的体内抑制白细胞三烯合成的MI治疗剂的组合物的组合,在具有包括黑非洲血统的种族的人类受试者中预防MI治疗的方法。 本发明还提供包含白三烯合成抑制剂和他汀类的组合物以及使用这些组合物降低患有MI,ACS,中风和/或PAOD风险的人类受试者中的C-反应蛋白的方法。